The i31-SLNB Identifies Patients with Cutaneous Melanoma Who Have Less than 5% Risk of SLN Positivity while the CP-GEP does not. (2025). SKIN The Journal of Cutaneous Medicine, 9(2), s563. https://doi.org/10.25251/skin.10.supp.563